As CDK9 is a master transcription regulator and a potential target in hematologic malignancies, the authors explored PRT2527 as a novel low nanomolar potent CDK9 inhibitor in B-ALL and CLL primary samples. This evidence concerns the gene CDK9 and B-cell chronic lymphocytic leukemia.